Earnings summaries and quarterly performance for Pennant Group.
Executive leadership at Pennant Group.
Board of directors at Pennant Group.
Research analysts who have asked questions during Pennant Group earnings calls.
Stephen Baxter
Wells Fargo & Company
5 questions for PNTG
Also covers: AGL, BTSG, CAH +15 more
Benjamin Hendrix
RBC Capital Markets
3 questions for PNTG
Also covers: ACHC, ADUS, AHCO +25 more
DM
David Macdonald
Truist Securities
3 questions for PNTG
Also covers: AVAH, ENSG, GRDN +3 more
Raj Kumar
Stephens
3 questions for PNTG
Also covers: ACHC, ADUS, ALHC +11 more
BH
Ben Hendricks
RBC Capital Markets
2 questions for PNTG
Also covers: ACHC, ADUS, BKD +11 more
Brian Tanquilut
Jefferies
2 questions for PNTG
Also covers: ACHC, ADUS, AHCO +31 more
SF
Scott Fidel
Stephens Inc.
2 questions for PNTG
Also covers: ACHC, ADUS, ALHC +17 more
JH
Jared Haase
William Blair & Company
1 question for PNTG
Also covers: ADUS, ALHC, BTSG +11 more
Recent press releases and 8-K filings for PNTG.
Pennant Group Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance
PNTG
Earnings
Guidance Update
M&A
- Pennant Group reported full year 2025 GAAP revenue of $947.7 million, adjusted EBITDA of $72.5 million, and adjusted diluted earnings per share of $1.18, meeting or exceeding its guidance.
- In Q4 2025, the home health and hospice segment's revenue increased 64.3% to $233.3 million and adjusted EBITDA grew 58.2% to $33.7 million. The senior living segment's Q4 revenue rose 19.6% to $56.1 million and adjusted EBITDA improved 46% to $6.1 million, with all-store occupancy reaching 80.6%.
- The company issued full year 2026 guidance projecting revenue between $1.13 billion and $1.17 billion, adjusted EBITDA from $88.5 million to $94.1 million, and adjusted earnings per share from $1.26 to $1.36.
- This 2026 guidance represents a 22.4% increase in revenue and a 26% increase in adjusted EBITDA at the midpoint, driven by organic growth and the ongoing integration of over 50 recently acquired locations, including the UnitedHealth transaction.
- Pennant Group maintains a strong financial position with a net debt to adjusted EBITDA ratio of 1.7 times and generated $48.3 million in cash flows from operations for the full year 2025.
4 days ago
Pennant Group Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance
PNTG
Earnings
Guidance Update
M&A
- Pennant Group reported full year 2025 revenue of $947.7 million and adjusted diluted earnings per share of $1.18, exceeding the midpoint of its updated annual guidance.
- Q4 2025 saw significant growth, with home health and hospice revenue increasing 64.3% to $233.3 million and senior living revenue up 19.6% to $56.1 million over the prior year quarter.
- Growth was fueled by strategic acquisitions, including Signature Healthcare at Home and over 50 locations from UnitedHealth and Amedisys, complemented by robust same-store growth across both segments.
- The company provided full year 2026 guidance, projecting revenue between $1.13 billion and $1.17 billion, adjusted EBITDA of $88.5 million to $94.1 million, and adjusted earnings per share of $1.26 to $1.36.
- Pennant Group ended 2025 with a strong balance sheet, reporting a net debt to adjusted EBITDA ratio of 1.7 times and $48.3 million in cash flow from operations for the full year.
4 days ago
Pennant Group Reports Strong Full Year 2025 Financial Results and Issues 2026 Guidance
PNTG
Earnings
Guidance Update
M&A
- Pennant Group reported full year 2025 revenue of $947.7 million, adjusted EBITDA of $72.5 million, and adjusted diluted earnings per share of $1.18, meeting or exceeding the midpoint of their updated guidance.
- For full year 2026, the company provided guidance for revenue of $1.13 billion-$1.17 billion, adjusted EBITDA of $88.5 million-$94.1 million, and adjusted earnings per share of $1.26-$1.36.
- Significant growth in 2025 was driven by acquisitions, including Signature Healthcare at Home and over 50 locations from UnitedHealth and Amedisys, with integration efforts for these new operations expected to continue through October 2026.
- Operationally, the Home Health and Hospice segment's Q4 2025 revenue increased by 64.3% to $233.3 million, and the Senior Living segment's Q4 2025 revenue grew by 19.6% to $56.1 million, with all-store occupancy rising to 80.6%.
- The company maintains a strong balance sheet with a net debt to adjusted EBITDA ratio of 1.7 times and generated $48.3 million in cash flows from operations for the full year 2025.
4 days ago
Pennant Group, Inc. Reports Record Q4 and Full-Year 2025 Results and Provides 2026 Guidance
PNTG
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Pennant Group, Inc. reported record financial performance for Q4 and full-year 2025, with total revenue increasing 53.2% to $289.3 million in Q4 2025 and 36.3% to $947.7 million for the full year. GAAP diluted earnings per share were $0.24 for Q4 2025 and $0.84 for full-year 2025.
- Operational growth was strong, with total home health admissions increasing 81.3% to 28,941 in Q4 2025 and hospice average daily census rising 46.9% to 5,060. Senior Living average occupancy also improved by 200 basis points to 80.6% in Q4 2025.
- The company provided 2026 annual guidance, projecting total revenue between $1,133.6 million and $1,171.8 million, adjusted earnings per diluted share between $1.26 and $1.36, and adjusted EBITDA between $88.5 million and $94.1 million.
- Management emphasized 2025 as a year of "record-breaking performance and growth" driven by strategic investments, with a focus on integrating new operations and operational excellence in 2026.
5 days ago
Pennant Group Announces Q4 and Fiscal Year 2025 Results and 2026 Guidance
PNTG
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Pennant Group reported GAAP diluted earnings per share of $0.24 for the fourth quarter of 2025 and $0.84 for the full year 2025, with adjusted diluted earnings per share of $0.34 for the quarter and $1.18 for the full year.
- Total revenue for the fourth quarter of 2025 was $289.3 million, an increase of 53.2% over the prior year quarter, and full year 2025 total revenue was $947.7 million, an increase of 36.3% over the prior year.
- The Home Health and Hospice Services segment revenue for the full year 2025 increased 41.0% to $732.7 million, and for the fourth quarter increased 64.3% to $233.3 million.
- For 2026, Pennant Group anticipates total revenue between $1,133.6 million and $1,171.8 million, adjusted earnings per diluted share between $1.26 and $1.36, and adjusted EBITDA between $88.5 million and $94.1 million.
5 days ago
Pennant Group Discusses 2025 Acquisitions, Integration, and Segment Performance
PNTG
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- The Pennant Group completed significant acquisitions in 2025, including the second tranche of the Signature acquisition and the Optum AMED Asset Divestiture, contributing to a productive year of revenue and earnings growth.
- The company anticipates a nine-quarter optimization period for acquisition integration, with G&A costs expected to increase in 2026 before normalizing to 6.5% by the end of 2026 from approximately 6.7% currently.
- Pro forma leverage is approximately two times net debt to adjusted EBITDA, with a target range of two to two and a half times, indicating additional capacity for future growth.
- Pennant has achieved a 20-25% differential between Managed Care (MA) and fee-for-service rates, significantly lower than the industry average of 35-40%, attributed to its 4.1 CMS Star Rating and strong preventable hospitalization rates.
- The Senior Living segment achieved all-time high occupancy in Q3 2025, successfully implementing high single-digit rate updates while increasing care charges, which now represent 20-25% of the business and are projected to reach 25-33%.
Nov 19, 2025, 8:00 PM
Pennant Group Discusses 2025 Growth, Acquisition Strategy, and Senior Living Performance
PNTG
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Pennant Group (PNTG) highlighted its 2025 growth initiatives, including the completion of the second tranche of the Signature acquisition in January and a significant portfolio purchase from UnitedHealth and Amedisys as part of a divestiture process.
- The company's strategy for integrating acquisitions involves a typical nine-quarter optimization period, and it aims to maintain a net debt to adjusted EBITDA leverage ratio between two and two and a half times, with a current pro forma ratio of approximately two times.
- PNTG's senior living segment achieved an all-time high in occupancy in Q3 2025 and is targeting a 15% EBITDA margin, with incremental occupancy gains expected to improve margins by 50-75 basis points.
- PNTG is actively pursuing joint venture partnerships with healthcare systems to expand its home health and hospice services and enhance care delivery.
Nov 19, 2025, 8:00 PM
The Pennant Group Reviews 2025 Acquisitions and Financial Strategy
PNTG
M&A
Debt Issuance
New Projects/Investments
- The Pennant Group experienced a productive 2025, driven by significant acquisitions, including the second tranche of the Signature acquisition and a large portfolio purchase from United and Amedisys divestiture, leading to revenue and earnings growth.
- The company's pro forma net debt to Adjusted EBITDA leverage ratio is approximately 2x, with a target range of 2x-2.5x. G&A costs are expected to increase in early 2026 for integration support but are projected to normalize to 6.5% by the end of 2026 from approximately 6.7% currently.
- Integration of new acquisitions, particularly in Home Health, typically involves a nine-quarter optimization period for implementing operating models, system integration, and rebranding.
- The Senior Living segment achieved an all-time high on occupancy in Q3, successfully implementing high single-digit rate increases by investing in facility improvements, clinical products, and activities programming. Healthcare services (care charges) account for 20%-25% of the Senior Living business, with potential for further growth.
Nov 19, 2025, 8:00 PM
Pennant Group Reports Strong Q3 2025 Results and Raises Full-Year Guidance
PNTG
Earnings
Guidance Update
M&A
- Pennant Group (PNTG) reported strong Q3 2025 results, with revenue of $229 million, an increase of 26.8%, adjusted EBITDA of $17.3 million, up 14.5%, and adjusted EPS of $0.30, up 15.4% over the prior year quarter.
- The company raised its full-year 2025 guidance, now anticipating revenue between $911.4 million and $948.6 million, adjusted EBITDA between $70.9 million and $73.8 million, and adjusted EPS between $1.14 and $1.18.
- PNTG completed the UnitedHealth Amedisys transaction on October 1, acquiring 54 locations with trailing 12-month revenues of $189.3 million for a purchase price of $146.5 million. This acquisition is expected to create some lumpiness in results through the transition.
- Both operating segments demonstrated strong performance in Q3 2025, with Home Health and Hospice segment revenue increasing 27.9% to $173.6 million and Senior Living segment revenue increasing 23.2% to $55.5 million. The Senior Living segment also achieved a record 80.9% all-store occupancy.
Nov 6, 2025, 5:00 PM
Pennant Group Expands Credit Facility to $350 Million
PNTG
Debt Issuance
New Projects/Investments
- On November 5, 2025, The Pennant Group, Inc. announced the expansion of its credit facility by $100 million, increasing the aggregate amount to $350 million.
- This expansion was facilitated by an incremental term loan A facility, with the proceeds primarily intended to refinance a portion of outstanding revolving loans and provide capacity for future growth.
- The incremental term loan shares the same interest rate and maturity date as the company's existing revolving facility.
Nov 5, 2025, 9:32 PM
Quarterly earnings call transcripts for Pennant Group.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more